Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established?∗∗Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
- 27 November 2000
- journal article
- editorial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 36 (7), 2096-2097
- https://doi.org/10.1016/s0735-1097(00)01026-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter studyJournal of the American College of Cardiology, 2000
- Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart FailureCirculation, 1999
- Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparisonEuropean Heart Journal, 1998
- Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?Journal of the American College of Cardiology, 1996
- ACE inhibitors for heart failure: a question of doseHeart, 1994
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart FailureNew England Journal of Medicine, 1991
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986